Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
Public ClinicalTrials.gov record NCT05248659. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy.
Study identification
- NCT ID
- NCT05248659
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Enrollment
- 600 participants
Conditions and interventions
Conditions
Interventions
- Sibeprenlimab 400 mg s.c. Q4weeks Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 4, 2022
- Primary completion
- Dec 27, 2028
- Completion
- Dec 30, 2029
- Last update posted
- May 4, 2026
2022 – 2029
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Site #336 | Birmingham | Alabama | 35233 | — |
| Clinical Research Site #325 | Los Angeles | California | 90027 | — |
| Clinical Research Site #370 | Palo Alto | California | 94304 | — |
| Clinical Research Site #330 | Denver | Colorado | 80220 | — |
| Clinical Research Site #323 | Lauderdale Lakes | Florida | 33313 | — |
| Clinical Research Site #373 | Atlanta | Georgia | 30342 | — |
| Clinical Research Site #356 | Lawrenceville | Georgia | 30046 | — |
| Clinical Research Site #369 | Boston | Massachusetts | 02114 | — |
| Clinical Research Site #331 | Worcester | Massachusetts | 01655 | — |
| Clinical Research Site #320 | Shelby | Michigan | 48315 | — |
| Clinical Research Site #346 | Great Neck | New York | 11021 | — |
| Clinical Research Site #350 | Columbus | Ohio | 43210 | — |
| Clinical Research Site #374 | Dakota Dunes | South Dakota | 57029 | — |
| Clinical Research Site #324 | Houston | Texas | 77030 | — |
| Clinical Research Site #361 | Milwaukee | Wisconsin | 53213 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 143 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05248659, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05248659 live on ClinicalTrials.gov.